[Effect of natural killer cell line NK-92 against human ovarian carcinoma cells in vitro and in vivo].
OBJECTIVE
To study the cytotoxic activity of NK-92 cells irradiated against human ovarian cancer.


METHODS
NK-92 cells were exposed to different doses of radiation and assayed for proliferation by a standard (3)H-thymidine incorporation assay and cell count by using trypan blue exclusion. The cytotoxic activity of NK-92 cells against targets was measured in a standard (51)Cr-release assay in vitro. The effectiveness of irradiated NK-92 cells on ovarian cancer was compared with the control group of cancers (without injection of irradiated NK-92 cells).


RESULTS
(1) In vitro:The proliferation of NK-92 cells was inhibited by radiation of 4, 8 and 16 Gy, respectively. From the (3)H-thymidine incorporation data, irradiation by 4 Gy reduced cell proliferation to 29% of control, while 8 Gy reduced proliferation to 6%. The cytotoxicity of NK-92 cells at 4 Gy 2 days following irradiation was approximately 42%-62% for ovarian cancer cell HO-8910, while it was 33%-58% at 8 Gy. (2) In vivo: Tumor size in treatment group was (0.047 +/- 0.019) cm(3) on day 30 after inoculation, and (0.167 +/- 0.021) cm(3) on day 40 and (0.343 +/- 0.022) cm(3) on day 50, while the sizes were smaller in treatment group (P < 0.01). In addition, the tumor group animals died between 74-82 days after injection of HO-8910 cells, while the treatment group animals were alive over 120 days (P < 0.01).


CONCLUSIONS
Our study indicates that injection of irradiated NK-92 cells may be a potentially effective treatment for human ovarian carcinoma.
Chen
Gang
G
Department of Obstetrics and Gynecology, Anhui Provincial Hospital, Hefei 230001, China.
Ling
Bin
B
Zhu
Huai-ping
HP
Zhao
Wei-dong
WD
Wang
Qun-hua
QH
Zhang
Hong-yan
HY
Wu
Ai-dong
AD
Wei
Hai-ming
HM
Tian
Zhi-gang
ZG
D000818:Animals; D002277:Carcinoma / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D007694:Killer Cells, Natural / Q000528:radiation effects*; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D014407:Tumor Cells, Cultured